Johnson & Johnson reports results for the quarter ended September 30 - Earnings Summary

Johnson & Johnson

13/10/2026 14:31

Johnson & Johnson JNJ.N reported quarterly adjusted earnings of $2.59​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $2.80.  The mean expectation of eighteen analysts for the quarter was for earnings of $2.54 per share. Wall Street expected results to range from $2.31  to $2.81 per share.
Revenue rose 5.9% to $25.40 billion from a year ago; analysts expected $25.28 billion. 
Johnson & Johnson's reported EPS for the quarter was 9 cents​.
The company reported quarterly net income of $210 million.
Johnson & Johnson shares had fallen by 0.4% this quarter and gained 27.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 16.1% in the last three months.​ 
In the last 30 days, ten analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Johnson & Johnson is $282.00, about 6.5% above its last closing price of $263.73
This summary was machine generated from LSEG data October 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
2.54
2.59
Beat
Jun. 30 2026 
2.85
2.90
Beat
Mar. 31 2026 
2.66
2.70
Beat
Dec. 31 2025 
2.44
2.46
Beat